[go: up one dir, main page]

DE602004005502D1 - Comt-inhibitoren - Google Patents

Comt-inhibitoren

Info

Publication number
DE602004005502D1
DE602004005502D1 DE602004005502T DE602004005502T DE602004005502D1 DE 602004005502 D1 DE602004005502 D1 DE 602004005502D1 DE 602004005502 T DE602004005502 T DE 602004005502T DE 602004005502 T DE602004005502 T DE 602004005502T DE 602004005502 D1 DE602004005502 D1 DE 602004005502D1
Authority
DE
Germany
Prior art keywords
comt
sup
diseases
compounds
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004005502T
Other languages
English (en)
Other versions
DE602004005502T2 (de
Inventor
Francois Diederich
Roland Jakob-Roetne
Christian Lerner
Ralph Paulini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of DE602004005502D1 publication Critical patent/DE602004005502D1/de
Application granted granted Critical
Publication of DE602004005502T2 publication Critical patent/DE602004005502T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/22—Pteridine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE602004005502T 2003-12-19 2004-12-13 Comt-inhibitoren Expired - Lifetime DE602004005502T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03104828 2003-12-19
EP03104828 2003-12-19
PCT/EP2004/014186 WO2005058228A2 (en) 2003-12-19 2004-12-13 Comt inhibitors

Publications (2)

Publication Number Publication Date
DE602004005502D1 true DE602004005502D1 (de) 2007-05-03
DE602004005502T2 DE602004005502T2 (de) 2007-11-29

Family

ID=34673618

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004005502T Expired - Lifetime DE602004005502T2 (de) 2003-12-19 2004-12-13 Comt-inhibitoren

Country Status (15)

Country Link
US (1) US7319101B2 (de)
EP (1) EP1697394B1 (de)
JP (1) JP2007514677A (de)
KR (1) KR100814737B1 (de)
CN (1) CN100447149C (de)
AT (1) ATE357453T1 (de)
AU (1) AU2004298343B2 (de)
BR (1) BRPI0417799A (de)
CA (1) CA2548300A1 (de)
DE (1) DE602004005502T2 (de)
ES (1) ES2282924T3 (de)
MX (1) MXPA06005894A (de)
PL (1) PL1697394T3 (de)
RU (1) RU2354655C2 (de)
WO (1) WO2005058228A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY148644A (en) 2005-07-18 2013-05-15 Orion Corp New pharmaceutical compounds
FR2893617A1 (fr) * 2005-11-24 2007-05-25 Inst Nat Sante Rech Med Analogues photoactivables du nadh, du nadph, du nad+ ou du nadp+
JP5210637B2 (ja) * 2005-11-29 2013-06-12 キッセイ薬品工業株式会社 新規なカテコール誘導体、それを含有する医薬組成物およびそれらの用途
US20090012177A1 (en) * 2006-03-23 2009-01-08 Rahim Shafa Treatment of psychiatric disorders using entacapone, tolcapone and other COMT inhibitor or MB-COMT inhibitor drugs
US8580762B2 (en) * 2010-12-03 2013-11-12 Epizyme, Inc. Substituted purine and 7-deazapurine compounds
TWI638802B (zh) 2012-05-24 2018-10-21 芬蘭商奧利安公司 兒茶酚ｏ－甲基轉移酶活性抑制化合物
KR101685862B1 (ko) 2012-12-27 2016-12-20 에프. 호프만-라 로슈 아게 Comt 억제제
US9175032B2 (en) 2013-03-15 2015-11-03 Epizyme, Inc. Methods of synthesizing substituted purine compounds
CN105218377B (zh) * 2015-09-14 2017-10-27 西安交通大学 一种羟基酪醇no供体衍生物及其制备方法和应用
CN108218796A (zh) * 2017-12-31 2018-06-29 佛山市赛维斯医药科技有限公司 含酰肼结构的化合物、制备方法及其用途
CN107973758A (zh) * 2017-12-31 2018-05-01 佛山市赛维斯医药科技有限公司 一类三嗪和酰肼结构的comt抑制剂、制备方法及其用途
CN107987025A (zh) * 2017-12-31 2018-05-04 佛山市赛维斯医药科技有限公司 一类含丙酰肼结构的化合物、制备方法及其用途
CN107987026A (zh) * 2017-12-31 2018-05-04 佛山市赛维斯医药科技有限公司 末端烯丙基的丙酰肼嘧啶结构的化合物、制备方法及其用途
CN108191775A (zh) * 2017-12-31 2018-06-22 佛山市赛维斯医药科技有限公司 一种末端烯丙基丙酰肼结构化合物及其用途
CN107903216A (zh) * 2017-12-31 2018-04-13 佛山市赛维斯医药科技有限公司 一种含丙酰肼和嘧啶结构的化合物及其用途
CN108148010A (zh) * 2017-12-31 2018-06-12 佛山市赛维斯医药科技有限公司 含酰肼结构的comt抑制剂、制备方法及其用途
CN108191783A (zh) * 2017-12-31 2018-06-22 佛山市赛维斯医药科技有限公司 一类苯甲胺三嗪结构的comt抑制剂、制备方法及其用途
CN108148004A (zh) * 2017-12-31 2018-06-12 佛山市赛维斯医药科技有限公司 一种含丙酰肼和嘧啶结构的化合物、制备方法及其用途
CN108129406A (zh) * 2017-12-31 2018-06-08 佛山市赛维斯医药科技有限公司 一种含末端烯键和酰肼结构的comt抑制剂及其用途
CN107935953A (zh) * 2017-12-31 2018-04-20 佛山市赛维斯医药科技有限公司 含末端烯键和酰肼结构的comt抑制剂、制备方法及其用途
CN117720405A (zh) * 2023-11-20 2024-03-19 长沙创新药物工业技术研究院有限公司 一种1-[3-氯-5-(三氟甲基)苯基]-2,2,2-三氟乙酮的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236952A (en) * 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
GB2238047B (en) * 1989-11-03 1993-02-10 Orion Yhtymae Oy Stable polymorphic form of (e)-n,n-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide and the process for its preparation
US5561134A (en) * 1990-09-25 1996-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties

Also Published As

Publication number Publication date
WO2005058228A2 (en) 2005-06-30
CN100447149C (zh) 2008-12-31
AU2004298343B2 (en) 2010-05-27
EP1697394A2 (de) 2006-09-06
ES2282924T3 (es) 2007-10-16
ATE357453T1 (de) 2007-04-15
BRPI0417799A (pt) 2007-04-17
RU2354655C2 (ru) 2009-05-10
RU2006125748A (ru) 2008-01-27
PL1697394T3 (pl) 2007-08-31
CN1886416A (zh) 2006-12-27
JP2007514677A (ja) 2007-06-07
DE602004005502T2 (de) 2007-11-29
AU2004298343A1 (en) 2005-06-30
KR20060103266A (ko) 2006-09-28
US20050137162A1 (en) 2005-06-23
KR100814737B1 (ko) 2008-03-19
MXPA06005894A (es) 2006-06-27
EP1697394B1 (de) 2007-03-21
US7319101B2 (en) 2008-01-15
CA2548300A1 (en) 2005-06-30
WO2005058228A3 (en) 2005-12-08

Similar Documents

Publication Publication Date Title
ATE357453T1 (de) Comt-inhibitoren
MXPA05008172A (es) Derivados de malonamida como inhibidores gamma-secretasa.
SE0202462D0 (sv) Novel use
IL179634A0 (en) 5-substituted-2-phenylamino-benzamides as mek inhibitor
TW200613306A (en) Imidazotriazines as protein kinase inhibitors
MX2009006756A (es) Derivados de 1-amino-metil-l-fenil-ciclohexano como inhibidores de dpp-iv.
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
JO2282B1 (en) Oxazole derivatives
WO2006044497A3 (en) Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
SE0202429D0 (sv) Novel Compounds
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
SE0301232D0 (sv) Novel use
MXPA04010055A (es) Derivados de tioxantina como inhibidores de mieloperoxidasa.
NO20063275L (no) Anvendelse av substituerte 2-aminotetraliner for forebyggende behandling av Parkinsons sykdom
IL195016A0 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
DE60221283D1 (de) Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden
WO2003070728A3 (en) Azabicyclo-substituted benzoylamides and thioamides for treatment of cns-related disorders
SG151336A1 (en) 1,3,4-oxadiazol-2-ones as ppar delta
AU2005313582A8 (en) Malonamide derivatives as inhibitors of gamma-secretase for the treatment of Alzheimer's disease
MA28562B1 (fr) 1,3,4-oxadiazol-2-ones comme modulateurs de ppar delta et leur utilisation
ATE451922T1 (de) Verwendung von thiazolidinon-derivaten zur behandlung von festen tumoren
ATE444069T1 (de) Chinolin-derivate zur behandlung von mglur5- rezeptor-vermittelten erkrankungen
SE0402591D0 (sv) Novel use
UA86873C2 (en) SUBSTITUTED ARYL 1,4-PYRAZlNE DERIVATIVES

Legal Events

Date Code Title Description
8364 No opposition during term of opposition